Allen R Comer

This inventor holds 18 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Skin Substitutes. Top assignees: Stratatech Corporation, Stratech Corporation, Wisconsin Alumni Research Foundation. Active years: 2005-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Allen R Comer. Retrieved from https://idiyas.com/inventor/allen-r-comer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 8)

% Patents Active = 94.4

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 91(Granted Patents)

Company Filing History:

13 out of 27

Stratatech Corporation

Wisconsin Alumni Research Foundation

patents

4. 3 out of 834,601

Other

patents

Years Active: 2005-2024

Loading Chart...

Areas of Expertise:

Skin Substitutes

Cryopreservation

Barrier Function

Angiogenic Growth Factors

Organotypically Cultured Tissue

Human Skin Equivalents

Wound Treatment

Irritancy Testing

NIKS Cells

Exogenous IL-12

Exogenous HIF-1α

Selective Inhibitors

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11911444 - Use of human skin substitutes expressing exogenous IL-12 to treat a wound bed (2024-02-27),

2. 11297829 - Cryopreservation of viable human skin substitutes (2022-04-12),

3. 10091983 - Cryopreservation of viable human skin substitutes (2018-10-09),

4. 9867904 - Dried and irradiated skin equivalents for ready use (2018-01-16),

5. 9526811 - Dried and irradiated skin equivalents for ready use (2016-12-27),

6. 8992997 - Dried and irradiated skin equivalents for ready use (2015-03-31),

7. 8808685 - Method of treatment using organotypically cultured skin tissue comprising NIKS cells that express exogenous HIF-1α (2014-08-19),

8. 8685463 - Dried and irradiated skin equivalents for ready use (2014-04-01),

9. 8580314 - Dried and irradiated skin equivalents for ready use (2013-11-12),

10. 7988959 - Method of treatment using organotypically cultured skin tissue comprising niks cells that express exogenous HIF-1a (2011-08-02),

11. 7955790 - Skin substitutes with improved barrier function (2011-06-07),

12. 7915042 - Keratinocytes expressing exogenous angiogenic growth factors (2011-03-29),

13. 7807148 - Organotypically cultured skin tissue comprising NIKS cells that express exogenous HIF-1a (2010-10-05),

14. 7501238 - Skin substitutes for irritancy testing (2009-03-10),

15. 7498167 - Keratinocytes expressing exogenous angiogenic growth factors (2009-03-03),

Title: Innovations by Allen R Comer: Pioneering Skin Substitute Technologies

Introduction

Allen R Comer, an accomplished inventor based in Madison, WI, has contributed significantly to the field of medical technology, particularly in the development of skin substitutes. With a total of 18 patents to his name, Comer has been at the forefront of innovations aimed at improving patient care, especially for those suffering from skin cancers.

Latest Patents

Among his latest patents, one notable invention is the "Use of human skin substitutes expressing exogenous IL-12 to treat a wound bed." This invention focuses on creating human skin substitutes that are engineered to express exogenous interleukin-12, offering innovative compositions and methods for treating patients who have either skin cancer or have recently undergone skin cancer excisions. Another significant patent is the "Cryopreservation of viable human skin substitutes," which presents systems and methods for preparing, storing, shipping, and utilizing skin equivalents crafted through organotypic culture. This innovation particularly addresses the need for cryopreserving viable skin substitutes, ensuring their effectiveness when applied to patients.

Career Highlights

Allen R Comer has made considerable strides in his career, working with leading companies in the medical technology sector. Notably, he has been associated with Stratatech Corporation, where he further developed his expertise in skin substitutes and related technologies.

Collaborations

Throughout his career, Comer has collaborated with prominent professionals in his field, including B Lynn Allen-Hoffmann and Michael R Hoffmann. These collaborations have bolstered his research and development efforts, leading to the successful creation of innovative medical solutions.

Conclusion

In conclusion, Allen R Comer’s contributions to the field of medical innovations, particularly through his patented technologies, reflect his commitment to advancing patient care. His work with human skin substitutes continues to pave the way for new treatment options for skin cancer patients, highlighting the importance of innovation in the medical community.

Profile summary based on public USPTO records.